U01 Pilot Trial of DUR-928 in Patients With Moderate and Severe Alcoholic Hepatitis
Latest Information Update: 20 Oct 2023
At a glance
- Drugs Larsucosterol (Primary)
- Indications Alcoholic hepatitis
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Acronyms DUR-928-AH
- 16 Oct 2023 Status changed from recruiting to completed.
- 08 Nov 2022 Planned End Date changed from 24 Sep 2023 to 24 Sep 2024.
- 08 Nov 2022 Planned primary completion date changed from 24 Sep 2022 to 24 Sep 2023.